SMR Congress | Conference

Future of Immunotherapy in Melanoma to Focus on Overcoming Resistance, Personalizing Regimens

October 29th 2020

With an estimated 5-year survival rate of 50% and an ongoing issue of resistance, next steps with immunotherapy in melanoma will focus on stratifying patients, personalizing therapy, and refining localized regimens.

Novel Triplets May Overcome Resistance to Targeted Therapy in BRAF+ Melanoma

October 29th 2020

The addition of anti–PD-1/PD-L1 to combination BRAF and MEK inhibition has been shown to improve progression-free survival and duration of response in patients with BRAF-mutated melanoma, suggesting potential to overcome resistance to targeted approaches.

Deeper Understanding of Disease Biology Needed in Melanoma to Move the Needle Forward

October 29th 2020

Jason J. Luke, MD, discusses the recent advancements with BRAF-targeted therapies and PD-1 checkpoint inhibitors in melanoma.

Dr. Luke on the Importance of BRAF in Melanoma

October 28th 2020

Jason J. Luke, MD, FACP, discusses the importance of BRAF in melanoma.

Dr. Weber on Results of the COMBI-AD Trial in Stage III BRAF-Mutant Melanoma

October 28th 2020

Jeffrey S. Weber, MD, PhD, discusses the results of the phase 3 COMBI-AD trial with dabrafenib plus trametinib in patients with resected, stage III BRAF V600E/K–mutant melanoma.

Spartalizumab Plus Dabrafenib/Trametinib Impresses in BRAF+ Melanoma With Poor Prognosis

November 27th 2019

A triplet combining the PD-1 inhibitor spartalizumab with dabrafenib and trametinib led to a 12-month overall survival rate of 86.1% for patients with previously untreated advanced BRAF V600–mutant melanoma.

Expert Weighs in on Targeted and Immunotherapy Combinations in Melanoma

November 26th 2019

Ryan J. Sullivan, MD, discusses the rationale for BRAF/MEK combinations and immunotherapeutic combinations in melanoma and ongoing research examining triplet regimens.

Expert Highlights Potential Markers of Nivolumab/Ipilimumab Response in Melanoma

November 26th 2019

Georgina V. Long, BSc, PhD, MBBS, FRACP, discusses the findings from a subgroup analyses of the CheckMate-067 trial.

Cobimetinib/Vemurafenib OS Benefit Sustained at 5 Years in BRAF+ Melanoma

November 25th 2019

The combination of cobimetinib (Cotellic) and vemurafenib (Zelboraf) maintained an advantage for overall survival and objective response rate in patients with BRAF-positive melanoma versus vemurafenib alone.

CR With Dabrafenib/Trametinib Linked to Long-Term Survival in BRAF+ Melanoma

November 24th 2019

Patients with unresectable or metastatic BRAF V600-mutant melanoma who achieve a complete response to dabrafenib (Tafinlar) plus trametinib (Mekinist) are more likely to have improved survival outcomes at 5 years.

x